A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

Sponsor
Seagen, a wholly owned subsidiary of Pfizer
Study ID
NCT06549816
Phase
PHASE1
Status
Completed

Conditions

  • Carcinoma, Non-Small Cell Lung
  • Esophageal Adenocarcinoma
  • Esophageal Squamous Cell Carcinoma
  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Squamous Cell Carcinoma of Head and Neck

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • sigvotatug vedotin — DRUG
    Sigvotatug vedotin is a antibody-drug conjugate (ADC) designed to deliver the cytotoxic agent monomethyl auristatin E (MMAE) to cells expressing integrin beta-6.

Study Details

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) to find out whether it is safe for Chinese participants who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how do Chinese participants' body interact with sigvotatug vedotin.

Key Dates

Start date
Aug 21, 2024
Status verified
Dec 2025
Primary completion
Nov 18, 2025
Completion
Nov 18, 2025

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: sigvotatug vedotin
    sigvotatug vedotin monotherapy 1.8 mg/kg adjusted ideal body weight intravenous administration on Days 1 and 15 of a 28-day cycle.

Primary Outcome Measure

Number of participants with adverse events (AEs) [ Time Frame: Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years ]

Related Studies